Terms: = Colorectal cancer AND BIRC3, AIP1, 330, ENSG00000023445, HIAP1, Q13489, MIHC, CIAP2, API2, cIAP2, MALT2, hiap-1, RNF49, HAIP1 AND Treatment
193 results:
1. Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated cancers in Patients With Type 2 Diabetes.
Wang L; Xu R; Kaelber DC; Berger NA
JAMA Netw Open; 2024 Jul; 7(7):e2421305. PubMed ID: 38967919
[TBL] [Abstract] [Full Text] [Related]
2. The nuclear export protein exportin-1 in solid malignant tumours: From biology to clinical trials.
Lai C; Xu L; Dai S
Clin Transl Med; 2024 May; 14(5):e1684. PubMed ID: 38783482
[TBL] [Abstract] [Full Text] [Related]
3. Squalene epoxidase promotes the chemoresistance of colorectal cancer via (S)-2,3-epoxysqualene-activated NF-κB.
Liu Q; Zhang Y; Li H; Gao H; Zhou Y; Luo D; Shan Z; Yang Y; Weng J; Li Q; Yang W; Li X
Cell Commun Signal; 2024 May; 22(1):278. PubMed ID: 38762737
[TBL] [Abstract] [Full Text] [Related]
4. [Relationship Between Tim-3 and Galectin-9 Expression Levels, Clinical Pathological Characteristics, and Prognosis in Patients After Radical Resection of colorectal cancer].
Zhang Y; Deng D; Yin W; Luo J; Liu J; Xie C; Ji X; Ma L; Zhang L; Xia X; Cheng S; Huang A; Yang F
Sichuan Da Xue Xue Bao Yi Xue Ban; 2024 Mar; 55(2):375-382. PubMed ID: 38645842
[TBL] [Abstract] [Full Text] [Related]
5. Circumventing drug resistance in gastric cancer: A spatial multi-omics exploration of chemo and immuno-therapeutic response dynamics.
Che G; Yin J; Wang W; Luo Y; Chen Y; Yu X; Wang H; Liu X; Chen Z; Wang X; Chen Y; Wang X; Tang K; Tang J; Shao W; Wu C; Sheng J; Li Q; Liu J
Drug Resist Updat; 2024 May; 74():101080. PubMed ID: 38579635
[TBL] [Abstract] [Full Text] [Related]
6. XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial.
Pan QZ; Zhao JJ; Liu L; Zhang DS; Wang LP; Hu WW; Weng DS; Xu X; Li YZ; Tang Y; Zhang WH; Li JY; Zheng X; Wang QJ; Li YQ; Xiang T; Zhou L; Yang SN; Wu C; Huang RX; He J; Du WJ; Chen LJ; Wu YN; Xu B; Shen Q; Zhang Y; Jiang JT; Ren XB; Xia JC
Signal Transduct Target Ther; 2024 Apr; 9(1):79. PubMed ID: 38565886
[TBL] [Abstract] [Full Text] [Related]
7. Management Strategies for Malignant Left-Sided Colonic Obstruction: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials and Propensity Score Matching Studies.
McHugh FT; Ryan ÉJ; Ryan OK; Tan J; Boland PA; Whelan MC; Kelly ME; McNamara D; Neary PC; O'Riordan JM; Kavanagh DO
Dis Colon Rectum; 2024 Jul; 67(7):878-894. PubMed ID: 38557484
[TBL] [Abstract] [Full Text] [Related]
8. High-tissue FRMD6 expression predicts better outcomes among colorectal cancer patients.
von Koskull A; Hagström J; Haglund C; Kaprio T; Böckelman C
Biomarkers; 2024 May; 29(3):127-133. PubMed ID: 38385211
[TBL] [Abstract] [Full Text] [Related]
9. Long-term outcomes of endoscopic or surgical resection in T1 colorectal cancer patients: a retrospective cohort study.
Song S; Dou L; Zhang Y; Liu X; Liu Y; He S; Wang G
Surg Endosc; 2024 Mar; 38(3):1499-1511. PubMed ID: 38242989
[TBL] [Abstract] [Full Text] [Related]
10. Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors.
Bauer TM; Santoro A; Lin CC; Garrido-Laguna I; Joerger M; Greil R; Spreafico A; Yau T; Goebeler ME; Hütter-Krönke ML; Perotti A; Juif PE; Lu D; Barys L; Cremasco V; Pelletier M; Evans H; Fabre C; Doi T
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38030303
[TBL] [Abstract] [Full Text] [Related]
11. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment for mismatch-repair-deficient (dMMR) or microsatellite-instability-high (MSI-H) advanced or metastatic colorectal cancer from the perspective of the Chinese health-care system.
Zhu C; Han G; Wu B
BMC Health Serv Res; 2023 Oct; 23(1):1083. PubMed ID: 37821934
[TBL] [Abstract] [Full Text] [Related]
12. MicroRNAs Regulate Inhibitor of Apoptosis Proteins (IAPs) in colorectal cancer.
Tanzadehpanah H; Avan A; Ghayour-Mobarhan M; Ferns GA; Manoochehri H; Sheykhhasan M; Mahaki H
Microrna; 2023; 12(3):210-220. PubMed ID: 37718526
[TBL] [Abstract] [Full Text] [Related]
13. A quality improvement project to optimize access to psychosocial care for cancer survivors who experience fear of recurrence.
Pereira L; Nguyen P; Benea A; Townsley C
J Psychosoc Oncol; 2023; 41(6):721-731. PubMed ID: 37702764
[TBL] [Abstract] [Full Text] [Related]
14. Radiation Therapy Changed the Second Malignancy Pattern in Rectal cancer Survivors.
Ye X; Tan Y; Ma R; Lou P; Yuan Y
Medicina (Kaunas); 2023 Aug; 59(8):. PubMed ID: 37629753
[No Abstract] [Full Text] [Related]
15. Anastasis enhances metastasis and chemoresistance of colorectal cancer cells through upregulating ciap2/NFκB signaling.
Wang R; Wang Y; Liu X; Liu M; Sun L; Pan X; Hu H; Jiang B; Zou Y; Liu Q; Gong Y; Wang M; Sun G
Cell Death Dis; 2023 Jun; 14(6):388. PubMed ID: 37391410
[TBL] [Abstract] [Full Text] [Related]
16. Cost-Effectiveness Analysis of Monoclonal Antibodies Associated With Chemotherapy in First-Line treatment of Metastatic colorectal cancer.
Barufaldi LA; de Albuquerque RCR; do Nascimento A; Martins LFL; Zimmermann IR; de Souza MC
Value Health Reg Issues; 2023 Sep; 37():33-40. PubMed ID: 37207532
[TBL] [Abstract] [Full Text] [Related]
17. Changing trends, clinicopathological characteristics, surgical treatment patterns, and prognosis of schistosomiasis-associated versus non-schistosomiasis-associated colorectal cancer: a large retrospective cohort study of 31 153 cases in Shanghai, China (2001-2021).
Zheng N; Wang H; Yu Q; Wang C; Bai CG; Pan AF; Jiang J; Lu J; Dai SM; Mei Z; Zhang W; Gao XH
Int J Surg; 2023 Apr; 109(4):772-784. PubMed ID: 36999800
[TBL] [Abstract] [Full Text] [Related]
18. Immune Activation following Irbesartan treatment in a colorectal cancer Patient: A Case Study.
Titmuss E; Milne K; Jones MR; Ng T; Topham JT; Brown SD; Schaeffer DF; Kalloger S; Wilson D; Corbett RD; Williamson LM; Mungall K; Mungall AJ; Holt RA; Nelson BH; Jones SJM; Laskin J; Lim HJ; Marra MA
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982943
[TBL] [Abstract] [Full Text] [Related]
19. Has_circ_0071803 promotes colorectal cancer progression by regulating miR-330-5p/MAPK signaling pathway.
Huang L; Dou G; Lu J; Chen Z; Wang J
Histol Histopathol; 2023 Dec; 38(12):1443-1451. PubMed ID: 36856372
[TBL] [Abstract] [Full Text] [Related]
20. Bevacizumab treatment for Metastatic colorectal cancer in Real-World Clinical Practice.
Dinu IM; Mihăilă M; Diculescu MM; Croitoru VM; Turcu-Stiolica A; Bogdan D; Miron MI; Lungulescu CV; Alexandrescu ST; Dumitrașcu T; Buică F; Luca IN; Lungulescu C; Negulescu MC; Gramaticu IM; Cazacu IM; Croitoru AE
Medicina (Kaunas); 2023 Feb; 59(2):. PubMed ID: 36837551
[No Abstract] [Full Text] [Related]
[Next]
